Table 2

Adverse events

Grade 1
N (%)
Grade 2
N (%)
Grade 3
N (%)
Nausea1 (5.6)1 (5.6)0
Headache1 (5.6)00
Chills2 (11.1)00
Nasal congestion1 (5.6)00
Fatigue4 (22.2)3 (16.6)0
Constipation1 (5.6)00
Hypersomnia02 (11.1)0
Hypophosphatemia02 (11.1)0
Anemia01 (5.6)1 (5.6)
Lung infection001 (5.6)
Dehydration1 (5.6)01 (5.6)
Hypotension1 (5.6)01 (5.6)
Sinus tachycardia1 (5.6)00
Atrioventricular block1 (5.6)00
Ear pain01 (5.6)0
Abdominal pain1 (5.6)1 (5.6)0
Diarrhea2 (11.1)00
Gastroesophageal reflux1 (5.6)00
Hemorrhoidal hemorrhage1 (5.6)00
Vomiting2 (11.1)1 (5.6)0
Edema limbs2 (11.1)00
Fever1 (5.6)00
Flu-like symptoms830
Malaise01 (5.6)0
Pain1 (5.6)00
Urinary tract infection01 (5.6)0
Injection-site reaction22 (100)7 (38.8)0
Creatinine increased1 (5.6)00
Lymphocyte count decreased01 (5.6)2 (11.1)
Weight loss1 (5.6)1 (5.6)0
Anorexia1 (5.6)2 (11.1)0
Hyperglycemia2 (11.1)00
Hyponatremia2 (11.1)00
Hypophosphatemia01 (5.6)0
Arthralgia01 (5.6)0
Back pain3 (16.7)00
Myalgia1 (5.6)1 (5.6)0
Non-cardiac chest pain1 (5.6)00
Dizziness3 (16.7)00
  • All adverse events are shown. N=number of events. There were no grade 4 treatment-related adverse events. Adverse event grade is according to the National Cancer Institute Common Terminology Criteria for Adverse Events V.5.0.